This week, the overall grades of three Pharmaceutical stocks are lower, according to the Portfolio Grader database. Each of these rates a "D" ("sell") or "F" overall ("strong sell"). More
Should I Buy Berkshire? 3 Pros, 3 Cons
Berkshire Hathaway's credit rating was cut from AA+ to AA because of an overreliance on its insurance business. Here are my three pros and cons for owning the stock. More
5 Stocks With Superb Analyst Earnings Revisions — LMCA WGO PIKE LCI ADNC
This week, these five stocks have the best ratings in Analyst Earnings Revisions, one of the eight Fundamental Categories on Portfolio Grader. More
Emerging Markets: A Hotbed for Vice Plays
Global consumption of (pricier) alcohol and tobacco products tends to go up right alongside increased incomes. These stocks naturally stand to reap the rewards. More
The News About Newspapers: It’s ‘Less Bad’
Long-embattled newspaper stocks are starting to see their print hemorrhaging slow, and operational diversity also is stemming the bleeding. Still, few are worth owning. More
Emerging-Market Bonds Are Looking Riskier By the Day
Certain segments of the emerging bond markets have compelling long-term potential, but low yields on government and corporate debt means that investors are no longer being paid for the risks. More
